- Home
- APP vs AMGN Comparison
APP vs AMGN Comparison
Compare APP & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APP
- AMGN
- Stock Information
- Founded
- APP 2012
- AMGN 1980
- Country
- APP United States
- AMGN United States
- Employees
- APP N/A
- AMGN N/A
- Industry
- APP EDP Services
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APP Technology
- AMGN Health Care
- Exchange
- APP Nasdaq
- AMGN Nasdaq
- Market Cap
- APP 158.0B
- AMGN 150.8B
- IPO Year
- APP 2021
- AMGN N/A
- Fundamental
- Price
- APP $584.00
- AMGN $275.94
- Analyst Decision
- APP Buy
- AMGN Hold
- Analyst Count
- APP 21
- AMGN 19
- Target Price
- APP $472.50
- AMGN $320.11
- AVG Volume (30 Days)
- APP 6.1M
- AMGN 2.0M
- Earning Date
- APP 11-05-2025
- AMGN 10-29-2025
- Dividend Yield
- APP N/A
- AMGN 3.44%
- EPS Growth
- APP 198.85
- AMGN 110.88
- EPS
- APP 7.03
- AMGN 12.23
- Revenue
- APP $5,737,591,000.00
- AMGN $34,917,000,000.00
- Revenue This Year
- APP $19.64
- AMGN $8.94
- Revenue Next Year
- APP $30.12
- AMGN $1.71
- P/E Ratio
- APP $79.98
- AMGN $22.60
- Revenue Growth
- APP 78.91
- AMGN 12.88
- 52 Week Low
- APP $97.35
- AMGN $253.30
- 52 Week High
- APP $587.88
- AMGN $339.17
- Technical
- Relative Strength Index (RSI)
- APP 80.43
- AMGN 36.65
- Support Level
- APP $560.79
- AMGN $275.16
- Resistance Level
- APP $587.88
- AMGN $282.94
- Average True Range (ATR)
- APP 19.86
- AMGN 4.43
- MACD
- APP 8.44
- AMGN -0.84
- Stochastic Oscillator
- APP 97.30
- AMGN 5.17
About APP Applovin Corporation
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max. AppLovin's primary tool for future growth is AXON 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.